FDA
-
-
-
-
-
-
-
Akebia begins dosing patients in Phase 1 trial of AKB-9090
-
-
-
-
-
-
-
Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook
-
-
-
-
-
-
-
Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients
-
-
-
-
-
-
-
Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology
-
-
-
-
-
-
-
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis
-
-
-
-
-
-
-
Akebia Therapeutics (AKBA) Reports CMS Grants TDAPA Reimbursement for Vafseo beginning January 1, 2025
-
-
-
-
-
-
-
Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

